Lipidomic Components Alterations of Human Follicular Fluid Reveal the Relevance of Improving Clinical Outcomes in Women Using Progesterin-Primed Ovarian Stimulation Compared to Short-Term Protocol

Xiaowei Wen, Yanping Kuang, Lixia Zhou, Baofeng Yu, Qiuju Chen, Yonglun Fu, Zheng Yan, Haiyan Guo, Qifeng Lyu, Jun Xie, Weiran Chai

Background: Increasing the success rate of in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI) is a duty of clinicians that has made many seek a variety of protocols. This study was undertaken to use a liquid chromatography-mass spectrometry (LC-MS) to define the alterations of follicular fluid (FF) lipid metabolites in patients undergoing progestin-primed ovarian stimulation (PPOS) compared with short-term protocol, revealing potential correlations between the differentially expressed lipids and ameliorative clinical outcomes.

Material/Methods: Ninety-three infertile women undergoing IVF/ICSI treatment with PPOS (n=62) or a short-term protocol ( n=31) were prospectively enrolled in a randomized controlled trial. FF samples were obtained from dominant follicles at the time of oocyte retrieval. Lipid metabolism profiles were analyzed using LC-MS.

Results: Twelve lipids were found to be higher in patients treated with the PPOS protocol than in those receiving the short-term protocol, including triacylglycerols (TAG-34: 1+NH₄, TAG-58: 0+NH₄, TAG-64: 3+NH₄, and TAG-64: 8+NH₄), diacylglycerol DAG-38: 6+NH₄, phosphatidylglycerols (PG-26: 0, PG-30: 2, and PG-40: 5), phosphatidylethanolamine PE-32: 2, lysophosphatidylethanolamine LPE-14: 1, lysophosphatidylinositol LPI-12: 0, and lysophosphatidylcholine LPC-16: 0.

Conclusions: Our data demonstrate that the PPOS protocol increases the levels of 12 lipids in FF, which reveals a strong association between the differentially elevated lipids and better IVF/ICSI outcomes.

MeSH Keywords: Follicular Fluid • Lipid Metabolism • Oocytes • Progesterone

Corresponding Authors: Weiran Chai, e-mail: chaiwrsh@126.com; Jun Xie, e-mail: Xiejun1968@126.com

Source of support: This work was supported by grants from the Science and Technology Commission of Shanghai Municipality (No. 15411953000, 15411964500, and 14411964300); the National Natural Science Foundation of China (No.81571397); and the Merck Serono Reproductive Medicine fund
Background

Follicular growth involves a complex pattern of hormonal signals regulated by the hypothalamus-pituitary-ovarian axis (HPOA) and by autocrine/paracrine signaling between oocytes and their adjacent somatic cells [1]. These processes have been utilized by assisted reproductive technology in the clinic for 30 years to help more infertile couples conceive. There are still many factors affecting the success rate of IVF/ICSI, especially premature LH surges, which lead to early ovulation, causing failure in up to 20% of patients undergoing IVF/ICSI [2,3]. Gonadotropin-releasing hormone (GnRH) agonists and antagonist have been used to reduce surface expression of the GnRH receptor in the pituitary or reduce GnRH sensitivity to prevent premature LH surges [4]. However, such protocols have increased the incidence of ovarian hyperstimulation syndrome and these surges range from 0.34% to 38% [5–7]. PPOS, created by Dr. Kuang, using medroxyprogesterone 17-acetate (MPA) negative feedback on the HPOA to inhibit the synthesis and secretion of pituitary LH [8–11]. This protocol is not only suitable for patients with a normal ovarian response, but has also been effectively applied in aged patients and those with low ovarian response and polycystic ovary syndrome.

The development of oocytes, fertilization, and early embryo cleavage are influenced by the composition of FF, which provides a microenvironment comprising a variety of nutrients [12]. The importance of FF in maintaining follicle development and oocyte quality has been extensively reported and discussed [13]. In particular, with the recent development in mass spectrometric technology, metabolomics has been transformed into a principal tool in biomedical research to decipher fine changes in FF metabolism in the potential of follicle and oocyte development. Nevertheless, there have been no studies published to date describing a detailed analysis of FF compositions following IVF/ICSI treatment with methods such as PPOS. As progestosterone (P) is also involved in the regulation of metabolism at multiple levels, such as glucose and lipoprotein lipase activity, we hypothesized that a LC-MS analysis of lipidic components alterations in progestin-primed ovarian stimulation protocol. The maximum age was 35 years old, basal follicle-stimulating hormone (FSH) levels were less than 10 IU/ml, antral follicles (AFC) were greater than or equal to 5, and all had a normal body mass index (BMI) and regular menstrual cycles (MC) (27–35 days). We excluded patients with infertility induced by male factor infertility or uterine or tubal factor infertility, or unexplained infertility. Women with polycystic ovary syndrome, premature ovarian failure, cancer, a history of no used embryo, and more than 3 degrees of endometriosis were also excluded. Women were recruited according to different protocols: 31 patients receiving the short-term protocol served as the control group; 62 women were enrolled in the PPOS protocols, including 28 women with PPOS (4 mg) and 34 with PPOS (10 mg), based on the dose of MPA, undergoing IVF/ICSI treatment.

Ethics approval and consent to participate

The study was approved by the Ethics Review Committee of the Ninth People’s Hospital of Shanghai and the Shanghai Jiaotong University Medical Center, China. Signed informed consent for use of FF was obtained from each patient after recommending conventional infertility treatment and the IVF/ICSI process.

Protocol

In PPOS protocol [14], MPA (Xianju Pharma, Zhejiang, China) 4 mg or 10 mg per day was taken orally from the MC3, and 150–225 IU human menopausal gonadotropin (hMG, Lizhu Pharmaceutical Trading Co., Zhuhai, China) until the day of induced ovulation. Depending on follicle development, we adjusted the dose of hMG. When the primary follicle reached 18 mm, 0.1 mg triptorelin (Huilin, Germany) and 2000–5000 IU human chorionic gonadotropin (hCG, Lizhu Pharmaceutical Trading Co., Zhuhai, China) were administrated to trigger ovulation. Transvaginal ultrasound-guided oocyte retrieval was performed 32–36 h later.

In the short-term protocol [15], triptorelin (Lizhu, Shanghai, China) 100 µg per day was injected from the MC3 until the day of hCG administration. Beginning on the day after the injection of triptorelin, 150–225 IU hMG was injected per day. Follicle development was monitored by ultrasound and we adjusted the dose of hMG based on the number and size of developing follicles. When the primary follicle reached 18 mm, or LH and P increased significantly compared with the baseline, 2000–5000 IU hCG was injected to trigger ovulation. Transvaginal ultrasound-guided oocyte retrieval was performed 32–36 h later.

Collection of follicular fluid

For each patient, the first follicle was carefully collected to avoid macroscopic blood contamination and a new needle was...
used for each patient. Each 3–5 mL of FF aspirate was centrifuged immediately at 2000 g for 20 min at 4°C, then the extracted FF supernatant was aliquoted (1.5 mL) and stored at −80°C prior to assay.

**Sample preparation**

Using methyl tert-butyl ether, we extracted the lipid molecules of follicular fluid twice. The organic phase was volatilized by the vacuum centrifugal concentration meter and the evaporated sample was redissolved by the mixed solvent. We transferred the redissolved samples to the sample vials for high performance liquid chromatography-electrospray time-of-flight mass spectrometry (HPLC-TOF-MS).

**Metabolomic analysis of follicular fluid**

The lipid molecules of follicular fluid samples were analyzed by HPLC-TOF-MS, which used a charged surface hybrid C18 chromatographic column as the chromatography/mass spectrum, 2.1×100 mm, 1.7 μm, flow velocity was 0.4 mL/min, and column temperature was held at 55°C. Gradient elution was used to elute the analyte, and we added 1-μL samples into the column conducted under electrospray ionization positive and negative ion mode. TOF/MS/MS was set to MS scanning, and total scan time cycle was 0.83 s.

**Metabolic correlation analysis**

Heat Map analyzed the metabolites and the similarity relation between samples to confirm which sample has a similar metabolic profile and metabolic path, and then gathered similar metabolites. The clustering software was R language (www.r-project.org) package Pheatmap. Correlation analysis was used for calculating coefficient of association among the metabolites, including each group of data matrix by Pearson's product–moment correlation and p-value of correcting by false discovery rate (FDR).

**Statistical analysis**

SPSS22.0 software was used for statistical analysis. Statistical analysis of normally distributed data was performed on 2 independent samples. The Mann-Whitney U test was used to measure non-normally distributed data. The categorical data were analyzed by chi-square test. LipidView (AB Scieix,1.2) software was utilized for lipid analysis by accurate mass and MS/MS fragment. LipidView software was used for quantitative results by comparing the target lipid peak area and their internal standard. To utilize quality control sample data for quality assurance analysis, Simca-P 13.0 (Umetrics AB, Umea, Sweden) software was used for principal component analysis (PCA). Then, partial least squares-discriminant analysis (PLS-DA) was applied to the data set, and after the construction of the PLS-DA models, a permutation test was used to prevent overfitting. Orthogonal partial least square-discriminate analysis (OPLS-DA) was applied to explore differences between the 3 groups of lipids. A 2-sample t test was used to assess differences between the 2 groups by R 3.3.0 (www.r-project.org), and P<0.05 and fold change >1.5 were regarded as indicating a significant difference.

**Results**

**Clinical characteristics of the patients**

A total of 93 women were recruited for the study. Table 1 shows characteristics of the 62 patients who underwent 1 of 2 PPOS protocols (4 or 10 mg) and the 31 control participants in the short-term protocol that were finally selected for inclusion in the study. There were no significant differences among the 3 groups with respect to age, infertility time, cause of infertility, basal hormone level, antral follicle count, percentage of primary infertility, previous IVF attempts, or body mass index. Furthermore, there were no significant differences in total doses of human menopausal and chorionic gonadotropins, the numbers of oocytes retrieved, the numbers of fertilizations and embryos, or the rates of clinical pregnancy. However, significant differences were found among groups for the total doses of MPA.

**Serum hormone of each groups**

The levels of serum hormones detected during ovarian stimulation with the PPOS and short-term protocols are presented in Figure 1. The levels of FSH in patients receiving ovarian stimulation with the PPOS protocol were higher than in those receiving the short-term protocol, appearing as a FSH surge on the trigger day. The levels of LH decreased in the PPOS protocol but increased and were maintained at a higher level in the short-term protocol. By contrast, the levels of estrogen (E2) and P were significantly lower with the PPOS protocol than with the short-term protocol. There were no significant differences between the 4-mg and 10-mg PPOS protocols.

**Overall lipid analysis and pattern recognition and functional analysis**

A total of 294 lipids, including 276 positive ions and 18 negative ions, were obtained according to the quality assurance, and 12 lipid molecules were identified, including PA, PC, PE, PG, PI, PS, CE, TAGs, DAGs, Cer, SM, and free fatty acids. A PCA revealed that the metabolic profiles from FF samples differed among the 3 groups. Furthermore, an OPLS-DA model with good predictability was applied to compare the PPOS and
short-term groups. These analyses revealed significant differences among the 3 groups (Figure 2).

**Differences in metabolites with ovarian stimulation**

Based on the OPLS-DA model, together with the p-value of the t test (p<0.05) and a greater that 1.5-fold difference, significant augmentation in the levels of 12 lipids metabolites were observed in the PPOS groups compared with the short-term group. As detailed in Figure 3, those lipids included triacylglycerols (TAG-34: 1+NH₄⁺, TAG-58: 0+NH₄⁺, TAG-64: 3+NH₄⁺, and TAG-64: 8+NH₄⁺), diacylglycerol DAG-38: 6+NH₄⁺, phosphatidylglycerols (PG-26: 0, PG-30: 2, and PG-40: 5), phosphatidylethanolamine PE-32: 2, lysophosphatidylinositol LPI-12: 0, and lysophosphatidylcholine LPC-16: 0.

Two-way hierarchical clustering of these metabolites revealed small differences within groups, with good sample repeatability. Overall, patterns of lipid expression in the PPOS groups differed significantly from that of the short-term group, with most

---

**Table 1. Clinical characteristics of the patients included in the study.**

| Parameter                        | Short-term n=31 | PPOS (4 mg) n=28 | PPOS (10 mg) n=34 | P-value 1 | P-value 2 |
|----------------------------------|-----------------|------------------|-------------------|-----------|-----------|
| Age                              | 31.9±2.8        | 30.7±3.1         | 31.2±2.9          | .298      | .592      |
| Infertility time                 | 2.9±3.8         | 2.2±1.3          | 2.7±2.0           | .109      | .252      |
| Basal FSH (IU/ml)                | 5.7±2.3         | 5.7±1.0          | 5.4±1.2           | .961      | .840      |
| Basal LH (IU/ml)                 | 3.3±1.4         | 3.5±1.2          | 3.8±1.0           | .836      | .113      |
| Basal E2 (pg/ml)                 | 27.3±20.5       | 28.8±20.0        | 25.5±16.7         | .810      | .738      |
| Basal P (ng/ml)                  | 0.4±1.0         | 0.3±0.1          | 0.3±0.2           | .920      | .487      |
| AFC (n)                          | 10.1±3.3        | 9.9±2.6          | 11.8±4.1          | .673      | .116      |
| Primary infertility (%)          | 54.1            | 52.4             | 53.8              | .133      | .106      |
| Previous IVF attempts (n)        | 0.9±1.4         | 1.0±1.1          | 0.9±1.5           | .929      | .966      |
| BMI (kg/m²)                      | 21.7±3.7        | 21.7±2.4         | 21.4±1.9          | .988      | .680      |
| Total dose of hMG (IU)           | 1702±138        | 1913±147         | 1894±345          | .149      | .372      |
| Total dose of hCG (IU)           | 2067±13099      | 2250±1357        | 2150±1182         | .878      | .809      |
| Total dose of MPA (mg)           | 0               | 36.3±5.0         | 90.0±12.9         | .000*     | .000*     |
| Oocytes retrieved (n)            | 11.5±9.9        | 14.1±13.8        | 14.6±26.1         | .143      | .473      |
| MII oocytes (n)                  | 9.2±0.9         | 10.8±0.7         | 10.9±0.4          | .980      | .847      |
| Fertilization (n)                | 7.7±0.6         | 8.7±0.7          | 8.8±0.5           | .066      | .078      |
| Clevage (n)                      | 7.6±0.6         | 8.7±0.7          | 8.8±0.5           | .066      | .078      |
| High-quality embryos             | 3.2±2.6         | 3.9±2.6          | 4.0±3.4           | .516      | .366      |
| All cryopreserved embryos (n)    | 3.2±2.5         | 3.9±2.5          | 4.0±3.3           | .523      | .368      |
| Biomedical pregnancy rate per transfer (%) | 48 (15/31)  | 57 (16/28)       | 58 (20/34)        | .217      | .164      |
| Clinical pregnancy rate (%)      | 42 (13/31)      | 50 (14/28)       | 50 (17/34)        | .242      | .205      |
| Birth weight (g)                 | 2998±223        | 3164±634         | 3116±755          | .245      | .432      |

Plus–minus values represent the mean ±SD. The categorical data were analysed by Chi-square. The baseline hormonal profile was typically assayed in patients treated with on menstrual days 2–4. P-value 1 for the comparison between short-term vs. PPOS (4 mg), P-value 2 for the comparison between short-term vs. PPOS (10 mg). AFC – antral follicles; BMI – body mass index; E2 – estrogen; FSH – follicle-stimulating hormone; hCG – human chorionic gonadotropin; hMG – human menopausal gonadotropin; LH – luteinizing hormone; MC – menstrual cycle day 3; MPA – medroxyprogesterone 17-acetate; P – progesterone; PPOS – progestin primed ovarian stimulation; * represent a statistically significant difference (P<0.05).
of the lipids showing upregulation with 10 mg PPOS (Figure 4A). Correlational analyses showed that there was a correlation between the selected variables and a high correlation between TAG-34: 1+NH4, TAG 58: 0+NH4, TAG 64: 3+NH4, TAG 64: 8+NH4 and DAG 38: 6+NH4 (Figure 4B).

Discussion

In this study, we performed LC-MS analysis of FF lipid composition from patients undergoing IVF/ICSI treatment with 4 or 10 mg PPOS or a short-term protocol. We identified 12 differentially expressed lipids that were associated with the dose of MPA in the PPOS treatment that achieved high-quality oocytes and satisfactory pregnancy outcomes. Future studies will reveal the mechanisms for the alteration in the lipid profile.

The main characteristic of the PPOS protocol is the use of a high dose of MPA to reduce LH levels to produce more follicles during the follicular phase. Although a study found that P can inhibit follicular activity in llamas by suppressing LH...
pulsatility [16], another study showed that P treatment correlates with the emergence of young follicles [17]. Moreover, the cumulus complex secretes P to promote follicle maturation, and this high P environment had no effect on the process of follicular development in humans [18]. Indeed, it is widely accepted that P can slow the frequency of LH secretion in the early stages of follicle development, effectively suppressing premature LH surges, but does not damage the follicular development at later stages [19–21]. Interestingly, PPOS also induced an increase in basal serum FSH by using hMG, which surged on the trigger day. Studies suggest that a surge in FSH before ovulation also promotes the development of the follicles, and the appearance of the FSH surge before ovulation effectively improves the developmental potential of follicles [22–24]. However, the underlying molecular mechanisms remain elusive.

Our analyses revealed that PGs, including PG-26: 0, PG-30: 2, and PG-40: 5, were higher in FF from patients treated with the PPOS protocol. PG is a lipid mediator synthesized by arachidonic acid in the cyclooxygenase pathway, which plays important roles in LH secretion, follicular development, fertilization, and blastocyst implantation [25,26]. Also, PGs are involved in mammalian ovulation by stimulating the follicular wall smooth muscle contraction, leading to follicular rupture and ovulation, which are mediated by the cAMP signaling system. Furthermore, a reduction of PGs results in many spermatozoa that cannot penetrate cumulus cells when levels of PGs are low [27–29]. Thus, the finding from our study of higher PG levels with the PPOS protocol is consistent with these results. PGs receptors located in many tissue cell membranes play a different function [30]. They mediate the physiological functions of PGs through their second messenger pathways, stimulating or inhibiting the activity of adenylate cyclase (AC) in the cell membrane to increase or decrease the level of cAMP. This suggests that PGs not only promote the ovulation of mature follicles, but also act as a second messenger of GnRH-mediated granule cells on cAMP response to promote the proliferation of follicular granulosa cells by mediating the PKA signaling pathway of the FSH in cells [31], which in turn plays an important role in the selection of dominant follicles.
Another important finding of our study was that levels of TAGs and DAGs in FF samples were increased by PPOS. As second messengers, these metabolites play important roles in cell signal transduction, proliferation, differentiation, and survival [32–34]. However, little is known about the effects of high TAG levels on human oocyte development. Animal studies have shown that TAGs can be used as the key energy source in bovine oocyte maturation and embryo development in vitro [35]. TAGs account for 60% of the neutral lipids in oocytes and accumulate with oocyte growth in the insect Rhodnius prolixus [36].
Future studies evaluating the relationship between TAG levels and human oocyte development are needed. With regard to DAGs, a previous study has shown that P stimulates Rana sp. oocytes to release large amounts of DAG [37]. Consistent with this, we found the IVF/ICSI treatment that induces high levels of P increases DAGs. Eckberg and Szuts similarly found that DAGs initiate the meiotic maturation of oocytes [38]. Furthermore, Albessard et al. found that levels of TAG, DAG, and PA were higher in ready-to-spawn ovaries than in spent females [39]. These findings demonstrate the crucial relationship between TAG and DAG, and the developmental potential of oocytes in a high P environment.

A remarkable finding of this study is the elevation of LPC and LPI. LPC can activate several second messengers, including extracellular-signal-regulated kinases and protein kinase C, which have been shown to be involved in the regulation of follicular development and oocyte maturation [40–42]. Likewise, LPI (specifically, LPI-12: 0), acts as a second messenger in the regulation of P and activates phosphoinositide 3-kinase signaling, which also modulates follicle development via the mammalian pre-implantation nutrition ligand, and is needed for cell survival and the first embryo division [43,44]. Therefore, we propose that the P-induced elevation of LPC and LPI levels in FF of the PPOS protocol regulates follicular development by activating several second messengers.

Our findings also showed that levels of PE and LPE were altered in FF by the PPOS protocol. However, further studies are needed to investigate the significance of these changes.

Conclusions

In conclusion, the results of these analyses demonstrate that use of the PPOS protocol alters the lipid profiles in FF. Moreover, these changes reveal the strong relevance of the differentially elevated lipids and better IVF/ICSI outcomes. The mechanisms by which these changes influence IVF/ICSI outcomes remain to be elucidated.

Acknowledgements

We also thank researcher Xiaoling Gao and doctor Xiaolin Wang for providing laboratory equipment in the Department of Pharmacology, Shanghai Jiaotong University School of Medicine, and all the clinical embryologists who helped with the collection of follicular fluid in the Shanghai Ninth People’s Hospital. We would like to thank not only the doctors and nurses, but also our patients and their families who assisted with recruitment for this study.

Conflicts of interests

None.

References:

1. Wu YT, Wu Y, Zhang JY et al: Preliminary proteomic analysis on the alterations in follicular fluid proteins from women undergoing natural cycles or controlled ovarian hyperstimulation. J Assist Reprod Genet, 2015; 32: 417–27
2. Macklon NS, Stouffer RL, Giudice LC, Fauser BC: The science behind 25 years of ovarian stimulation for in vitro fertilization. Endoor Rev, 2006; 27: 170–207
3. Choi MH, Cha SH, Park CW, Kim JY et al: The effectiveness of earlier oocyte retrieval in the case of a premature luteinizing hormone surge on hCG day in in vitro fertilization–embryo transfer cycles. Clin Exp Reprod Med, 2013; 40: 90–94
4. Nayot D, Klahook S, Casper RF: Nimodipine, a calcium channel blocker, delays the spontaneous LH surge in women with regular menstrual cycles: A prospective pilot study. Reprod Biol Endocrinol, 2013; 11: 95–97
5. Sills ES, Collins GS, Salem SA, Jones CA et al: Balancing selected medication costs with total number of daily injections: A preference analysis of GnRH-agonist and antagonist protocols by IVF patients. Reprod Biol Endocrinol, 2012; 10: 2–8
6. Mourad S, Brown J, Farquhar C: Interventions for the prevention of OHSS in ART cycles: an overview of Cochrane reviews. Cochrane Database Syst Rev, 2017; 1: 2–10
7. Reichman DE, Zakarin L, Chao K et al: Diminished ovarian reserve is the predominant risk factor for gonadotropin-releasing hormone antagonist failure resulting in breakthrough luteinizing hormone surges in in vitro fertilization cycles. Fertil Steril, 2014; 102: 99–102
8. Kuang Y, Chen Q, Hong Q et al: Luteal-phase ovarian stimulation case report: Three-year follow-up of a twin birth. J IVF Reprod Med Genet, 2013; 1: 106
9. Kuang Y, Hong Q, Chen Q et al: Luteal-phase ovarian stimulation is feasible for producing competent oocytes in women undergoing IVF/ICSI treatment, with optimal pregnancy outcomes in frozen-thawed embryo transfer cycles. Fertil Steril, 2014; 101: 105–11
10. Kuang Y, Chen Q, Fu Y et al: Medroxyprogesterone acetate is an effective oral alternative for preventing premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation for in vitro fertilization. Fertil Steril, 2015; 104: 62–70
11. Massin N: New stimulation regimens: endogenous and exogenous proges- terone use to block the LH surge during ovarian stimulation for IVF. Hum Reprod Update, 2017; 23: 211–20
12. Wallace M, Cottell E, Gibney MJ et al: An investigation into the relationship between the metabolic profile of follicular fluid, oocyte development, and implantation outcome. Fertil Steril, 2012; 97: 1078–84
13. Ambekar AS, Kelkar DS, Pinto SM et al: Proteomics of follicular fluid from women with polycystic ovary syndrome suggests molecular defects in follicular development. J Clin Endocrinol Metab, 2015; 100: 744–53
14. Wang Y, Chen Q, Wang N et al: Controlled ovarian stimulation using medroxyprogesterone acetate and hMG in patients with polycystic ovary syn- drome treated for IVF: A double-blind randomized crossover clinical trial. Medicine (Baltimore), 2016; 95: 29–39
15. Wang N, Wang Y, Chen Q et al: Luteal-phase ovarian stimulation vs. con- ventional ovarian stimulation in patients with normal ovarian reserve treat- ed for IVF: A large retrospective cohort study. Clin Endocrinol, 2016; 84: 720–28
16. MV Cavilla, CP Bianchi, F Aguilera et al: Hormonal changes and follicular activity after treatment with intravaginal progesterone-releasing devices in llamas. Reprod Dom Anim, 2014; 51: 1–10
17. Adams GP, Matteri RL, Kastelic JP et al: Association between surges of follicle-stimulating hormone and the emergence of follicular waves in heifers. J Reprod Fertil, 1992; 94: 177–88
18. Venetis CA, Kolibianakis EM, Bosdou JK et al: Basal serum progesterone and history of elevated progesterone on the day of hCG administration are significant predictors of late follicular progesterone elevation in GnRH antagonist IVF cycles. Hum Reprod, 2016; 31: 1859–65
19. Soules MR, Steiner RA, Clifton DK et al: Progestosterone modulation of pulsatile luteinizing hormone secretion in normal women. J Clin Endocrinol Metab, 1984; 158: 378–83
20. Letterie GS: Inhibition of gonadotropin surge by a brief midcycle regimen of ethinyl estradiol and norethindrone: possible role in in vitro fertilization. Gynecol Endocrinol, 2000; 14: 1–4
21. Dong I, Wang Y, Chai WR et al: The pregnancy outcome of progesterone-primed ovarian stimulation using medroxyprogesterone acetate 4mg versus 10mg daily in infertile women undergoing in vitro fertilization: A randomized controlled trial. Biol Reprod, 2017; 9: 1471-0528
22. Breen SM, Knox RV: The impact of dose of FSH (Folltropin) containing LH on ovulation rate, pregnancy rate, and litter size in mice. Theriogenology, 2012; 78: 28–38
23. Lamb JD, Shen S, McCulloch C et al: Follicle-stimulating hormone administration at the time of human chorionic gonadotropin trigger improves oocyte developmental competence in in vitro fertilization cycles: A randomized, double-blind, placebo-controlled trial. Fertil Steril, 2011; 95: 1655–60
24. Molina I, Pla M, Vicente JS et al: Induction of ovulation in rabbits with pure urinary luteinizing hormone and human chorionic gonadotrophin: comparison of oocyte and embryo quality. Hum Reprod, 1991; 6: 1449–52
25. Mannock DA, Lewis RN, McMullen TP, McElhaney RN: The effect of variation in LH/LUTropin on follicular development, estrus and ovulation responses in prepubertal gilts. Anim Reprod Sci, 2012; 132: 193–200
26. Takahashi T, Fujimori C, Hagiwara A, Ogiwara K: Recent advances in the understanding of teleost medaka ovulation: The roles of proteases and prostaglandins. Zoolog Sci, 2013; 30: 239–47
27. Lean II, Porter JA, Rabiee AR et al: Comparison of effects of GnRH and prostaglandin in combination, and prostaglandin on conception rates and time to conception in dairy cows. Aust Vet J, 2003; 81: 488–93
28. Tamba S, Yodoi R, Segi-Nishida E et al: Timely interaction between prostaglandin and chemokine signaling is a prerequisite for successful fertilization. Proc Natl Acad Sci USA, 2008; 105: 14539–44
29. Yi D, Zeng S, Guo Y: A diet rich in n-3 polysaturated fatty acids reduced prostaglandin biosynthesis, ovulation rate, and litter size in mice. Theriogenology, 2012; 78: 28–38
30. Narumiya S, Sugimoto Y, Ushikubi F: Prostanoid receptors: Structures, properties and functions. Physiol Rev, 1999; 79: 1193–226
31. Jin YM, Zhang CQ, Lin XH, Zeng W: Prostaglandin involvement in follicle-stimulating hormone-induced proliferation of granulosa cells from chicken prepubertal follicles. Prostaglandins Other Lipid Mediat, 2006; 81: 45–54
32. Norris SE, Friedrich MG, Mitchell TW et al: Human prefrontal cortex phospholipids containing docosahexaenoic acid increase during normal adult aging, whereas those containing arachidonic acid decrease. Neurobiol Aging, 2015; 36: 1659–69
33. Cui G, Staron MM, Gray SM et al: L7-1 induced glycerol transport and TAG synthesis promotes memory CD8+ T cell longevity. Cell, 2015; 161: 750–61
34. Mattaini KR, Brignole EJ, Kini M et al: An epitope tag alters phosphoglycerate dehydrogenase structure and impairs ability to support cell proliferation. Cancer Metab, 2015; 3: 2–12
35. Ferguson EM, Leese HJ: A potential role for triglyceride as an energy source during bovine oocyte maturation and early embryo development. Mol Reprod Dev, 2006; 73: 1195–201
36. Santos R, Rosas-Oliveira R, Saraiva FB et al: Lipid accumulation and utilization by oocytes and eggs of Rhodius prololis. Arch Insect Biochem Physiol, 2011; 77: 1–16
37. Morrill GA, Ma GY, Kostelow AB: Progestosterone-induced phospholipid N-methylation and sphingomyelin synthesis in the amphibian oocyte plasma membrane: A second source of the 1,2-diacylglycerol second messenger associated with the G2/M transition. Biochim Biophys Acta, 1994; 1224: 1249–56
38. Eckberg WR, Szuts EZ: Diacylglycerol content of Chaeopterus oocytes during maturation and fertilization. Dei Biol, 1993; 159: 732–35
39. Abasserd A, Mayzaud P, Cuzin-Roudy I: Variation of lipid classes among organs of the Northern krill Meganyctiphanes norvegica, with respect to reproduction. Comp Biochem Physiol A Mol Integr Physiol, 2001; 129: 373–90
40. Drissner D, Kunze G, Callewaert N et al: Lyso-phosphatidylcholine is a signal in the arbuscular mycorrhizal symbiosis. Science, 2007; 318: 265–68
41. Sriraman V, Modi SR, Bodenburg RH et al: Identification of ERK and JNK as signaling mediators on protein kinase C activation in cultured granulosa cells. Endocrinol, 2008; 294: 52–60
42. Moreira F, Corcini CD, Mondadori RG et al: Leptin and mitogen-activated protein kinase (MAPK) in oocytes of sows and gilts. Anim Reprod Sci, 2013; 139: 89–94
43. Tokumura A, Miyake M, Nishikoa Y et al: Production of lysophosphatidic acids by lysophosphatidase D in human follicular fluids of in vitro fertilization patients. Biol Reprod, 1999; 61: 195–99
44. Buckingham KL, Stone PR, Smith JF, Chamley LW: Antiphospholipid antibodies in serum and follicular fluid is there a correlation with IVF implantation failure? Hum Reprod, 2006; 21: 728–34

This work is licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)